Bluejay begins phase 3 trial of brelovitug for hepatitis D
Written by
PharmaTimes
Published
0
comments
0
min
First patient enrolled in AZURE-2 study comparing brelovitug to Hepcludex First patient enrolled in AZURE-2 study comparing brelovitug to Hepcludex